![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C20H23F4N3O |
Molar mass | 397.418 g·mol−1 |
3D model (JSmol) | |
| |
|
CBS-0550 is a drug developed byTaisho Pharmaceutical, which acts as a potent and selectivecannabinoidCB2receptoragonist, with 1400x selectivity for CB2 over the relatedCB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produceanalgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]
![]() | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |